Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial Meeting Abstract
| Authors: | Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; Colombo, N.; Chudecka-Głaz, A. M.; Grimm, C.; Lheureux, S.; Van Nieuwenhuysen, E.; Heitz, F.; Wenham, R. M.; Ushijima, K.; Day, E.; Aghajanian, C. |
| Abstract Title: | Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100029 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA5506 |
| Notes: | Meeting Abstract: LBA5506 -- Meeting was also available virtually -- Source: Wos |
